leadf
logo-loader
viewEvgen Pharma PLC
(
AIM:EVGFRA:8EV
)

Evgen Pharma updates on the ‘STAR’ trial for Covid-19, Glioma research and key breast cancer drug

Evgen Pharma PLC (LON:EVG) Chief Executive Dr Huw Jones talks to Proactive London following an abundance of news from the clinical-stage drug development company. Jones talks through the ‘STAR’ trial updates which now have a total of 56 patients in Dundee. The aim is to reach 100 patients, which will be assessed with acute respiratory infections, including those with coronavirus (COVID-19). Specifically, researchers will investigate whether SFX-01 can reduce the severity, or prevent the onset of acute respiratory distress syndrome (ARDS) in pneumonia patients.

Quick facts: Evgen Pharma PLC

Follow
AIM:EVG

Price: 6.115 GBX

Market Cap: £16.81 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Evgen portfolio update on core field of cancer, 'the R&D is entirely on plan...

Evgen Pharma PLC's (LON:EVG) Dr Huw Jones joins Proactive London to go through their portfolio with progress for is lead asset on two fronts in the field of cancer. Jones firstly addresses the results of the ‘STAR’ Covid-19 trial of its lead asset, ‘SFX-01' which was implemented as an...

on 21/7/21

2 min read